If you have been reading about anti-doping analysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
== Biography == Yourcenar was born in Brussels, Belgium, as Marguerite Antoinette Jeanne Marie Ghislaine Cleenewerck de Crayencour, to Michel Cleenewerck de Crayencour and Fernande de Cartier de Marchienne. Her father was of French bourgeois descent, originating from French Flanders, and a wealthy landowner. Her mother, of Belgian nobility, died ten days after Marguerite's birth. She grew up in the home of her paternal grandmother, and adopted the surname Yourcenar as a pen name; in 1947, she also took it as her legal surname. Yourcenar's first novel, Alexis, was published in 1929. She translated Virginia Woolf's The Waves over a ten-month period in 1937. In 1939, her partner at the time, the literary scholar and Kansas City native Grace Frick, invited Yourcenar to the United States to escape the outbreak of World War II in Europe. She lectured in comparative literature in New York City and Sarah Lawrence College. Yourcenar and Frick became lovers in 1937 and remained together until Frick's death in 1979. After ten years spent in Hartford, Connecticut, they bought a house in Northeast Harbor, Maine, on Mount Desert Island, where they lived for decades. They are buried next to each other at Brookside Cemetery, Somesville, Mount Desert, Maine. Yourcenar's last companion was Jerry Wilson, with whom she had a tormented relationship; he died of AIDS in 1986. In 1951, Yourcenar published, in France, the novel Memoirs of Hadrian, which she had been writing on and off for a decade. The novel was an immediate success and met with critical acclaim.
Thus, glutathione acts unusually as a coenzyme and is required only in catalytic (i.e., very small) amounts; normally, glutathione acts instead as a redox couple in oxidation-reduction reactions. The glyoxalase system has also been suggested to play a role in regulating cell growth and in assembling microtubules.
Ubiquitin molecules are cleaved off the protein immediately prior to destruction and are recycled for further use. Although the majority of protein substrates are ubiquitylated, there are examples of non-ubiquitylated proteins targeted to the proteasome. The polyubiquitin chains are recognised by a subunit of the proteasome: S5a/Rpn10. This is achieved by a ubiquitin-interacting motif (UIM) found in a hydrophobic patch in the C-terminal region of the S5a/Rpn10 unit. Lysine 63-linked chains are not associated with proteasomal degradation of the substrate protein. Instead, they allow the coordination of other processes such as endocytic trafficking, inflammation, translation, and DNA repair. In cells, lysine 63-linked chains are bound by the ESCRT-0 complex, which prevents their binding to the proteasome. This complex contains two proteins, Hrs and STAM1, that contain a UIM, which allows it to bind to lysine 63-linked chains. Methionine 1-linked (or linear) polyubiquitin chains are another type of non-degradative ubiquitin chains. In this case, ubiquitin is linked in a head-to-tail manner, meaning that the C-terminus of the last ubiquitin molecule binds directly to the N-terminus of the next one. Although initially believed to target proteins for proteasomal degradation, linear ubiquitin later proved to be indispensable for NF-kB signaling. Currently, there is only one known E3 ubiquitin ligase generating M1-linked polyubiquitin chains - linear ubiquitin chain assembly complex (LUBAC).
=== Hydrogen bromide === The simplest compound of bromine is hydrogen bromide, HBr. It is mainly used in the production of inorganic bromides and alkyl bromides, and as a catalyst for many reactions in organic chemistry. Industrially, it is mainly produced by the reaction of hydrogen gas with bromine gas at 200–400 °C with a platinum catalyst. However, reduction of bromine with red phosphorus is a more practical way to produce hydrogen bromide in the laboratory:
== Adverse effects and contraindications == Like other antiarrhythmics, ibutilide can lead to abnormal heart rhythms due to its ability to prolong the QT interval, which can lead to the potentially fatal abnormal heart rhythm known as torsades de pointes. Consequently, the drug is contraindicated in patients that are likely to develop abnormal heart rhythms; this includes individuals who have previously experienced polymorphic ventricular tachycardia, have a prolonged QT interval, sick sinus syndrome, or have recently had a myocardial infarction, among other conditions.
Sources: en.wikipedia.org
==== Strategies for EPS yield-increase ==== Although the EPS from microalgae have many potential applications, their low yield is one of the major limitations for scale-up in industry. The type and amount of EPS obtained from a certain microalgae-culture depends on several factors, such as culture system design, nutritional and culture conditions, as well as the recovery and purification process. Therefore, the configuration and optimization of production systems are critical for the further development of applications. Examples of successful increase of EPS yield include
In conclusion, of the 15 patients who had completed treatment, 7 developed varying degrees of hepatic failure and lactic acidosis and 5 died. Investigations found that affected patients suffered depletion of mitochondrial DNA (mtDNA) in both liver and muscle tissue, establishing mitochondrial dysfunction as a contributing mechanism to the observed toxicity. The FDA conducted a study into whether adverse effects could have been predicted beforehand. However, Dr. A Weinstein concluded that there was no way in which these adverse effects could have been predicted in laboratory animal studies or studies on patients.
In biochemistry, two biopolymers are antiparallel if they run parallel to each other but with opposite directionality (alignments). An example is the two complementary strands of a DNA double helix, which run in opposite directions alongside each other. Nucleic acid molecules have a phosphoryl (5') end and a hydroxyl (3') end. This notation follows from organic chemistry nomenclature, and can be used to define the movement of enzymes such as DNA polymerases relative to the DNA strand in a non-arbitrary manner.
{\displaystyle {\ce {^{99}_{39}Y ->[\beta^-][1.47\,{\ce {s}}] ^{99}_{40}Zr ->[\beta^-][2.1\,{\ce {s}}] ^{99}_{41}Nb ->[\beta^-][15.0\,{\ce {s}}] ^{99}_{42}Mo ->[\beta^-][65.94\,{\ce {h}}] ^{99}_{43}Tc ->[\beta^-][211,100\,{\ce {y}}] ^{99}_{44}Ru}}}
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.